2. Signaling Pathways
  3. Vitamin D Related/Nuclear Receptor
  4. Estrogen Receptor/ERR
  5. Estrogen Receptor/ERR Ligand

Estrogen Receptor/ERR Ligand

Estrogen Receptor/ERR Isoform Comparison

Estrogen Receptor/ERR Ligands (7):

Cat. No. Product Name Effect Purity
  • HY-107245
    Segetalin B
    		Ligand 99.51%
    Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP).
  • HY-163467
    CHEMBL4224880
    		Ligand
    CHEMBL4224880 is an estrogen receptor-α (ER-α) binder.
  • HY-170334
    ER ligand-7
    		Ligand
    ER ligand-7 is the ligand for estrogen receptor, and can be used for synthesis of PROTAC ER Degrader-15 (HY-170332) as ligand for target protein.
  • HY-170339
    ER ligand-5
    		Ligand
    ER ligand-5 is the ligand for estrogen receptor, that can be used as ligand for target protein for PROTAC synthesis of PROTAC ERα Degrader-10 (HY-170336).
  • HY-W615671
    4,4'-(Cyclohexylidenemethylene)diphenol
    		Ligand
    4,4'-(Cyclohexylidenemethylene)diphenol (Compound 2) is a symmetric cyclic nonsteroidal estrogen. 4,4'-(Cyclohexylidenemethylene)diphenol has high binding affinity for estrogen receptors ERα and ERβ.
  • HY-49537
    ER ligand-10
    		Ligand
    ER ligand-10 (Compound 11a) is a weak ERa and ERβ ligand, and shows weak estrogenic activity.
  • HY-171477
    Metahexestrol
    		Ligand
    Metahexestrol is an estrogen receptor (E2R) inhibitor with antitumor activity. It significantly inhibits the proliferation of estrogen receptor-positive MCF-7 human breast cancer cells (ED50 = 1.0 μM). Additionally, Metahexestrol also exhibits inhibitory effects in estrogen receptor-negative MDA-MB-231 cells, and its antiproliferative activity cannot be reversed by estrogen, suggesting that its mechanism of action may be partially independent of the E2R pathway. Metahexestrol can be used in research on estrogen-dependent breast cancer.